ABSTRACT
Objective To investigate the clinical effect of noninvasive mechanical ventilation in the treatment of chronic obstructive pulmonary disease (COPD) and the expression of insulin-like growth factor (IGF) Ⅰ, Ⅱand cathepsin B (CB) in patients.Methods 89 patients with chronic obstructive pulmonary disease from January2014 to June 2017 in the hospital for treatment were retrospectively chosen as the research objects. They were randomly divided into the control group (n = 43) and the study group (n = 46). The control group was treated with conventional therapy. The study group was treated with noninvasive mechanical ventilation on the basis of the control group. The observation period was 10 days of treatment, the level of the indicators of lung function, arterial blood gas changes of the both groups were detected, and the clinical treatment efficiency was taken for statistics. At the same time, the levels of IGF-Ⅰ, Ⅱ and CB in patients were analyzed.Results (1) The lung function of the study group: the lung function VC [ (302.72 ± 40.79) m L], the maximum expiratory flow PEF (421.72 ± 37.59) L/min], and the first expiratory volume FEV1 [ (83.24 ± 11.65) ％], were significantly higher than that of the control group (P＜0.05). (2) The arterial blood gas in the study group: arterial oxygen partial pressure (PaO2) [ (99.24 ± 10.16) mm Hg], partial pressure of carbon dioxide (PaCO2) [ (43.32 ± 5.37) mm Hg], oxygenation index (PaO2/FiO2) [ (281.02 ± 19.74) ％ ], were better than the level of detection in the control group (P＜0.05). (3) The effective rate of clinical treatment was 93.48％ in the study group, which was significantly higher than that in the control group of 67.44％ (P＜0.05). (4) The IGF-Ⅰ [ (11.47 ± 1.53) ug/L] and IGF-Ⅱ [ (28.27± 11.49) ug/L] in the study group were lower than those in the control group, while CB [ (1.03 ± 0.24) ng/ml]was higher than that of the control group (P＜0.05).Conclusions Noninvasive mechanical ventilation is helpful to clear the recovery of lung function in patients with chronic obstructive pulmonary disease, can alter the abnormal expression of insulin-like growth factor I, II and cathepsin B levels in patients, and the clinical treatment effect is significant.